Literature DB >> 11442311

Possible role of TNF on procalcitonin release in a baboon model of sepsis.

H Redl1, A Schiesser, E Tögel, M Assicot, C Bohuon.   

Abstract

Procalcitonin (PCT) has been described as an early and discriminating marker of bacteria-associated sepsis in patients. However, little is known of its source and actions, especially with regard to its relation to tumor necrosis factor (TNF). TNF is responsible for the release of several other mediators of sepsis e.g., chemokines. We tested the hypothesis that plasma PCT levels during sepsis differ with regard to the degree of TNF availability. Severe hyperdynamic sepsis was induced in baboons (n = 14) by i.v. infusion of live E. coli (approximately 2 x 10(9) colony-forming units/kg) over 2 h. Animals were pretreated 2 h before E. coli either with 1 mg/kg humanized anti-TNF antibody (CDP571) or placebo (Ringer solution). Plasma PCT levels at baseline was barely detectable, but increased to about 4000 pg/mL at 4 h after E. coli infusion. Levels were maximal between 8 and 24 h and had returned nearly to baseline at 72 h. Although no TNF could be measured in the treated group, PCT levels were not different between the placebo and the TNF antibody treatment group. We conclude that PCT levels are not dependent on the systemic presence of TNF in an E. coli sepsis model in baboons. Such sepsis induced PCT release is clearly different from the previously reported PCT release during infusion of rhTNF in volunteers or chimpanzees.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11442311     DOI: 10.1097/00024382-200116010-00005

Source DB:  PubMed          Journal:  Shock        ISSN: 1073-2322            Impact factor:   3.454


  8 in total

Review 1.  Procalcitonin in sepsis and systemic inflammation: a harmful biomarker and a therapeutic target.

Authors:  Kenneth L Becker; Richard Snider; Eric S Nylen
Journal:  Br J Pharmacol       Date:  2009-11-27       Impact factor: 8.739

2.  Does procalcitonin have a role in the pathogenesis of nasal polyp?

Authors:  Suat Bilici; Zehra Cinar; Ozgur Yigit; Mustafa Cakir; Enes Yigit; Hafize Uzun
Journal:  Eur Arch Otorhinolaryngol       Date:  2019-02-09       Impact factor: 2.503

3.  Variability of voriconazole concentrations in patients with hematopoietic stem cell transplantation and hematological malignancies: influence of loading dose, procalcitonin, and pregnane X receptor polymorphisms.

Authors:  Guangting Zeng; Linlin Wang; Lihong Shi; Huilan Li; Miaomiao Zhu; Jia Luo; Zanling Zhang
Journal:  Eur J Clin Pharmacol       Date:  2020-01-14       Impact factor: 2.953

4.  Effect of hyperglycaemia on inflammatory and stress responses and clinical outcome of pneumonia in non-critical-care inpatients: results from an observational cohort study.

Authors:  Philipp Schuetz; Natalie Friedli; Eva Grolimund; Alexander Kutz; Sebastian Haubitz; Mirjam Christ-Crain; Robert Thomann; Werner Zimmerli; Claus Hoess; Christoph Henzen; Beat Mueller
Journal:  Diabetologia       Date:  2013-11-24       Impact factor: 10.122

5.  Values of procalcitonin and C-reactive proteins in the diagnosis and treatment of chronic obstructive pulmonary disease having concomitant bacterial infection.

Authors:  Yanyan Li; Linlin Xie; Shuzhen Xin; Kaishu Li
Journal:  Pak J Med Sci       Date:  2017 May-Jun       Impact factor: 1.088

6.  Prognostic significance of procalcitonin in small cell lung cancer.

Authors:  Kosuke Ichikawa; Satoshi Watanabe; Satoru Miura; Aya Ohtsubo; Satoshi Shoji; Koichiro Nozaki; Tomohiro Tanaka; Yu Saida; Rie Kondo; Satoshi Hokari; Nobumasa Aoki; Yasuyoshi Ohshima; Toshiyuki Koya; Toshiaki Kikuchi
Journal:  Transl Lung Cancer Res       Date:  2022-01

7.  Induction of procalcitonin in liver transplant patients treated with anti-thymocyte globulin.

Authors:  Roman Zazula; Miroslav Prucha; Tomas Tyll; Eva Kieslichova
Journal:  Crit Care       Date:  2007       Impact factor: 9.097

8.  Plasma procalcitonin is associated with all-cause and cancer mortality in apparently healthy men: a prospective population-based study.

Authors:  Ovidiu S Cotoi; Jonas Manjer; Bo Hedblad; Gunnar Engström; Olle Melander; Alexandru Schiopu
Journal:  BMC Med       Date:  2013-08-13       Impact factor: 8.775

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.